Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial Evaluating the Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB2210 Injection in Subjects With Advanced Malignant Tumors

NCT06929195 is registered in ClinicalTrials.gov with Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06929195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06929195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial Evaluating the Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB2210 Injection in Subjects With Advanced Malignant Tumors
Lead sponsor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
May 16, 2025
Completion date
April 10, 2026
Enrollment
16 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant tumours